vinflunine and best supportive care
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transitional Cell Carcinoma of the Urothelial Tract
Conditions
Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms
Trial Timeline
Jul 1, 2005 → Jan 1, 2008
NCT ID
NCT00315237About vinflunine and best supportive care
vinflunine and best supportive care is a phase 3 stage product being developed by Bristol Myers Squibb for Transitional Cell Carcinoma of the Urothelial Tract. The current trial status is completed. This product is registered under clinical trial identifier NCT00315237. Target conditions include Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00315237 | Phase 3 | Completed |
Competing Products
20 competing products in Transitional Cell Carcinoma of the Urothelial Tract
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine | Astellas Pharma | Phase 1/2 | 41 |
| Pemetrexed + Gemcitabine + Platinol | Eli Lilly | Phase 1/2 | 41 |
| Vepugratinib + EV + Pembrolizumab | Eli Lilly | Phase 3 | 77 |
| durvalumab and tremelimumab | AstraZeneca | Phase 2 | 52 |
| Docetaxel + vandetanib + Placebo | AstraZeneca | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Everolimus + Everolimus + Paclitaxel | Novartis | Phase 2 | 52 |
| Buparlisib | Novartis | Phase 2 | 52 |
| BEZ235 | Novartis | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Gemcitabine + Cisplatin + Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Nivolumab/Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| vinflunine | Bristol Myers Squibb | Phase 2 | 51 |
| Dasatinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Docetaxel + Oxaliplatin | Sanofi | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2/3 | 64 |
| Rogaratinib (BAY1163877) + Chemotherapy | Bayer | Phase 2/3 | 62 |
| CG0070 Adenovirus Vector | CG Oncology | Phase 2/3 | 62 |